Jiang Pi | Immunotherapy | Best Researcher Award

Assoc Prof Dr. Jiang Pi | Immunotherapy | Best Researcher Award

Assoc Prof Dr. Jiang Pi, School of Medical Technology, Guangdong Medical University, China

Assoc. Prof. Dr. Jiang Pi appears to be a strong candidate for the Best Researcher Award based on the following qualifications:

Publication profile

Research Excellence:

Dr. Jiang Pi has made significant contributions to the fields of biomaterials, nanotechnology, and targeted drug delivery, particularly in developing innovative therapies for tuberculosis and cancer. His work has resulted in numerous high-impact publications in leading journals, demonstrating a strong research output and expertise.

Recognition and Honors:

 Dr. Jiang has been listed among the world’s top 2% scientists for three consecutive years (2021-2023). This recognition highlights his influence and contribution to his field on a global scale.

Leadership and Editorial Roles:

As Vice Dean at Guangdong Medical University, Dr. Jiang shows leadership in academia. His editorial roles in high-impact journals like Pharmacological ResearchFrontiers in Pharmacology, and others reflect his active involvement and recognition in the scientific community.

Postdoctoral and Academic Training:

His extensive training, including a postdoctoral research position at the University of Illinois, Chicago, provides a solid foundation for his research.

Scientific Funding and Projects:

 Dr. Jiang Pi has secured significant research funding, underscoring his capability to lead and manage research projects successfully.

Publication Top Notes  

  • 🦠 Roles of HIF-1α signaling in Mycobacterium tuberculosis infection: New targets for anti-TB therapeutics?
    Authors: Li, C., Wang, J., Xu, J.-F., Pi, J., Zheng, B.
    Source: Biochemical and Biophysical Research Communications, 2024, 711, 149920.
    📚
  • 🌿 Intratracheal Administration of Stem Cell Membrane-Cloaked Naringin-Loaded Biomimetic Nanoparticles Promotes Resolution of Acute Lung Injury
    Authors: Jin, H., Zhao, Y., Yao, Y., Pi, J., Huang, G.
    Source: Antioxidants, 2024, 13(3), 282.
    📚 Cited by: 2
  • 🧠 Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures
    Authors: Yao, H., Wang, X., Chi, J., Pi, J., Xu, J.-F.
    Source: Molecules, 2024, 29(5), 964.
    📚 Cited by: 1
  • 🧬 Zinc Oxide-Selenium Nanoparticles for Inhibiting the Proliferation of Porcine Reproductive and Respiratory Syndrome Virus
    Authors: Xu, Y., Li, Q., Chen, Y., Zhou, L., Liu, J.
    Source: ACS Applied Nano Materials, 2024, 7(4), pp. 3734–3747.
    📚 Cited by: 2
  • 💊 Oral delivery of pH-sensitive nanoparticles loaded Celastrol targeting the inflammatory colons to treat ulcerative colitis
    Authors: Zhao, Y., Yao, Y., Fan, S., Huang, G., Jin, H.
    Source: Journal of Tissue Engineering, 2024, 15.
    📚
  • 🦠 Identification and Validation of Genes Related to Macrophage Polarization and Cell Death Modes Under Mycobacterium tuberculosis Infection
    Authors: Yang, Z., Wang, J., Pi, J., Zhao, Y., Wang, Y.
    Source: Journal of Inflammation Research, 2024, 17, pp. 1397–1411.
    📚
  • 🦠 Macrophage targeted iron oxide nanodecoys augment innate immunological and drug killings for more effective Mycobacterium Tuberculosis clearance
    Authors: Shen, L., Liao, K., Yang, E., Xu, J.-F., Pi, J.
    Source: Journal of Nanobiotechnology, 2023, 21(1), 369.
    📚 Cited by: 2
  • 📈 Advances of Long Non-Coding RNAs as Potential Biomarkers for Tuberculosis: New Hope for Diagnosis?
    Authors: Xia, J., Liu, Y., Ma, Y., Xu, J.-F., Pi, J.
    Source: Pharmaceutics, 2023, 15(8), 2096.
    📚 Cited by: 3

Conclusion

Dr. Jiang Pi’s profile demonstrates the qualifications, recognition, and impact necessary for consideration in the Best Researcher Award.

Dr Gabriel Espinosa Carrasco | Immunotherapy | Best Researcher Award

 Gabriel Espinosa Carrasco | Immunotherapy | Best Researcher Award

Dr at Memorial Sloan Kettering Cancer Center,Spain.

Dr. Gabriel Espinosa Carrasco is a distinguished immunologist affiliated with Memorial Sloan Kettering Cancer Center. His research primarily focuses on T cell activation and the mechanisms of self-antigen recognition in immunology. Dr. Espinosa Carrasco’s work advances our understanding of immune responses in various contexts, bridging the gap between basic science and clinical applications.

Profile:

orcid

Education:

  1. Ph.D. in Biological Sciences and Immunology (2011-2016)
    University of Montpellier, INSERM Unit 1183 (France)
    Title: CD8+ and CD4+ T cell activation in response to self-antigens: from the lymphoid tissue to the target organ.
  2. Master in Advanced Immunology (2010-2011)
    University of Barcelona (UB), Barcelona (Spain)
  3. Bachelor’s Degree in Biology (2004-2010)
    Autonomous University of Barcelona (UAB), Barcelona (Spain)

Research Experience:

  1. Post-doctoral Scholar (2022-now)
    Cancer Virotherapy and Immunotherapy Group, Bellvitge Institute for Biomedical Research (IDIBELL)
    Department: Molecular Mechanisms and Experimental Therapy in Oncology
    Supervisor: Dr. Ramon Alemany
    🌟 Focus: Investigating novel virotherapy and immunotherapy approaches for cancer treatment.
  2. Post-doctoral Research Scholar (2017-2022)
    Memorial Sloan-Kettering Cancer Center, Immunology Program, New York
    Project: Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
    Supervisor: Dr. Andrea Schietinger
    🔬 Focus: Enhancing the effectiveness of immunotherapies in solid tumors.
  3. Ph.D. Student (2011-2016)
    INSERM Unit 1183, Montpellier
    Projects:
    a) Study the cooperation of effector CD8+ and CD4+ T cells in pancreas infiltration and beta cell destruction in real-time.
    b) Role of bacterial product translocation in the breakdown of CD8+ T cell peripheral tolerance under lymphopenic conditions.
    Supervisor: Dr. Javier Hernández
    📚 Focus: Understanding T cell interactions and their role in autoimmune responses.
  4. Master Internship (2010-2011)
    Institute of Biotechnology and Biomedicine, Barcelona
    Analysis of peptides directory associated with HLA class I molecules from human thymus and spleen.
    Supervisor: Dr. Iñaki Alvarez
    🔬 Focus: Peptide analysis and immune recognition.
  5. Bachelor’s Internship (2008-2009)
    Institute of Biotechnology and Biomedicine, Barcelona
    Composition analysis of the HLA-DR-associated human thymus peptidome.
    Supervisor: Dr. Iñaki Alvarez
    🔬 Focus: Immune system peptide composition.

Research Interests:

Dr. Espinosa Carrasco’s research primarily focuses on T cell activation, self-antigen recognition, and the development of new therapeutic strategies for autoimmune diseases and cancer immunotherapy. His work aims to elucidate the complex interactions within the immune system to enhance treatment efficacy

Awards and Honors:

  • 2024: Provisionally selected for the “Best Researcher Award 2024” (ACA awards)
  • 2022: Selected Speaker, Recent insights into Immuno-Oncology, Leuven, Belgium
  • 2021-2022: Grant recipient, Ludwig Center Basic and Translational Immunology Postdoctoral RFA Memorial Sloan Kettering Cancer Center, New York, USA. $100,000/year
  • 2019: Third prize poster presentation award, Tumor Microenvironments: Mechanisms and Therapeutic Implication 6th Annual Symposium, New York, USA
  • 2017: Invited seminar speaker, Georgetown University, Department of Microbiology and Immunology
  • 2016: Excelente Cum Laude Tesis Doctoral, University of Montpellier, Montpellier, France
  • 2015: Best poster presentation award, Institute for Regenerative Medicine and Biotherapy Annual Retreat, Montpellier, France
  • 2014: Travel Grant, European Association for the Study of Diabetes conference
  • 2012-2015: Research grant from the French Ministry of Research (MRT scholarship), €21,000/year
  • 2009-2010: ERASMUS scholarship from the Autonomous University of Barcelona (UAB), University of Nancy

Publications:

  • Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell, 2024. Link.
  • TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med, 2022. Link.
  • Fate bifurcation of beta cell-specific CD8 T cells drives type 1 diabetes. Nature, 2022. Link.
  • Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci USA, 2019. Link.
  • Integrin beta 1 optimizes diabetogenic T cell migration and function in the pancreas. Frontiers in Immunology, 2018. Link.
  • CD4+ T helper cells play a key role in maintaining diabetogenic CD8+ T cell function in the pancreas. Frontiers in Immunology, 2018. Link.
  • Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell interplay. Theranostics, 2018. Link.
  • PPARβ/δ directs the therapeutic potential of mesenchymal stem cells in arthritis. Annals of the Rheumatic Diseases, 2016. Link.
  • Metabolism Regulates Exposure of Pancreatic Islets to Circulating Molecules In Vivo. Diabetes, 2016. Link.
  • Systemic LPS Translocation Activates Cross-Presenting Dendritic Cells but Is Dispensable for the Breakdown of CD8+ T Cell Peripheral Tolerance in Irradiated Mice. PLoS One, 2015. Link.